CircRNA circ_0005273 contributes to the cisplatin resistance of cervical cancer cells by sponging miR-133b

References

• Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J, et al. 2020. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet. Global Health 8:e191–e203.
   PubMed Web of Science ®Google Scholar
• Aufiero S, Reckman YJ, Pinto YM, Creemers EE. 2019. Circular RNAs open a new chapter in cardiovascular biology. Nature Reviews. Cardiology 16:503–514.
   PubMed Web of Science ®Google Scholar
• Chen LL. 2020. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nature Reviews. Molecular Cell Biology 21:475–490.
   PubMed Web of Science ®Google Scholar
• Chen X, Yang T, Wang W, Xi W, Zhang T, Li Q, et al. 2019. Circular RNAs in immune responses and immune diseases. Theranostics 9:588–607.
   PubMed Web of Science ®Google Scholar
• Cui C, Yang J, Li X, Liu D, Fu L, Wang X. 2020. Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance. Molecular Cancer 19:58.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. 2014. Cisplatin in cancer therapy: molecular mechanisms of action. European Journal of Pharmacology 740:364–378.
   PubMed Web of Science ®Google Scholar
• Dong M, Li P, Xie Y, Wang Z, Wang R. 2021. CircMYBL2 regulates the resistance of cervical cancer cells to paclitaxel via miR-665-dependent regulation of EGFR. Drug Development Research 82:1193–1205.
   PubMed Web of Science ®Google Scholar
• Ghosh S. 2019. Cisplatin: the first metal based anticancer drug. Bioorganic Chemistry 88:102925.
   PubMed Web of Science ®Google Scholar
• Guan Y, Zhang Y, Hao L, Nie Z. 2020. CircRNA_102272 promotes cisplatin-resistance in hepatocellular carcinoma by decreasing miR-326 targeting of RUNX2. Cancer Management and Research 12:12527–12534.
   PubMed Web of Science ®Google Scholar
• Hou YS, Li X. 2020. Circ_0005273 induces the aggravation of pancreatic cancer by targeting KLF12. European Review for Medical and Pharmacological Sciences 24:11578–11586.
   PubMed Web of Science ®Google Scholar
• Huang W, Lu Y, Wang F, Huang X, Yu Z. 2020. Circular RNA circRNA_103809 accelerates bladder cancer progression and enhances chemo-resistance by activation of miR-516a-5p/FBXL18 axis. Cancer Management and Research 12:7561–7568.
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. 2019. The biogenesis, biology and characterization of circular RNAs. Nature Reviews. Genetics 20:675–691.
   PubMed Web of Science ®Google Scholar
• Kumar L, Harish P, Malik PS, Khurana S. 2018. Chemotherapy and targeted therapy in the management of cervical cancer. Current Problems in Cancer 42:120–128.
   PubMed Web of Science ®Google Scholar
• Li D, Xia L, Chen M, Lin C, Wu H, Zhang Y, et al. 2017. MiR-133b, a particular member of myomiRs, coming into playing its unique pathological role in human cancer. Oncotarget 8:50193–50208.
   PubMedGoogle Scholar
• Lin C, Xie L, Lu Y, Hu Z, Chang J. 2018. MiR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells. International Journal of Molecular Medicine 41:2050–2058.
   PubMed Web of Science ®Google Scholar
• Liontos M, Kyriazoglou A, Dimitriadis I, Dimopoulos MA, Bamias A. 2019. Systemic therapy in cervical cancer: 30 years in review. Critical Reviews in Oncology/Hematology 137:9–17.
   PubMed Web of Science ®Google Scholar
• Lv L, Li Q, Chen S, Zhang X, Tao X, Tang X, et al. 2019. MiR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L. Experimental Cell Research 385:111597.
   PubMed Web of Science ®Google Scholar
• Makovec T. 2019. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiology and Oncology 53:148–158.
   PubMed Web of Science ®Google Scholar
• Pan JY, Sun CC, Bi ZY, Chen ZL, Li SJ, Li QQ, et al. 2017. MiR-206/133b cluster: a weapon against lung cancer? Molecular Therapy. Nucleic Acids 8:442–449.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. 2020. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians 70:7–30.
   PubMed Web of Science ®Google Scholar
• Song H, Liu D, Dong S, Zeng L, Wu Z, Zhao P, et al. 2020. Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduction and Targeted Therapy 5:193.
   PubMed Web of Science ®Google Scholar
• Tay Y, Rinn J, Pandolfi PP. 2014. The multilayered complexity of ceRNA crosstalk and competition. Nature 505:344–352.
   PubMed Web of Science ®Google Scholar
• Thomson DW, Dinger ME. 2016. Endogenous microRNA sponges: evidence and controversy. Nature Reviews. Genetics 17:272–283.
   PubMed Web of Science ®Google Scholar
• Wang X, Ji C, Hu J, Deng X, Zheng W, Yu Y, et al. 2021. Hsa_circ_0005273 facilitates breast cancer tumorigenesis by regulating YAP1-hippo signaling pathway. Journal of Experimental & Clinical Cancer Research: CR 40:29.
   PubMed Web of Science ®Google Scholar
• Yang H, Li X, Meng Q, Sun H, Wu S, Hu W, et al. 2020. CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer. Molecular Cancer 19:13.
   PubMed Web of Science ®Google Scholar
• Zhang K, Zhou H, Yan B, Cao X. 2020. TUG1/miR-133b/CXCR4 axis regulates cisplatin resistance in human tongue squamous cell carcinoma. Cancer Cell International 20:148.
   PubMed Web of Science ®Google Scholar
• Zhang S, Cheng J, Quan C, Wen H, Feng Z, Hu Q, et al. 2020. CircCELSR1 (hsa_circ_0063809) contributes to paclitaxel resistance of ovarian cancer cells by regulating FOXR2 expression via miR-1252. Molecular Therapy. Nucleic Acids 19:718–730.
   PubMedGoogle Scholar
• Zhang W, Zhang H, Zhao X. 2020. Circ_0005273 promotes thyroid carcinoma progression by SOX2 expression. Endocrine-Related Cancer 27:11–21.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yang T, Xiao J. 2018. Circular RNAs: promising biomarkers for human diseases. EBioMedicine 34:267–274.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zheng R, Chen J, Ning D. 2020. CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC). Cancer Cell International 20:289.
   PubMed Web of Science ®Google Scholar
• Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. 2016. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Design, Development and Therapy 10:1885–1895.
   PubMed Web of Science ®Google Scholar
• Zou FW, Yang SZ, Li WY, Liu CY, Liu XH, Hu CH, et al. 2020. CircRNA_001275 upregulates Wnt7a expression by competitively sponging miR-370-3p to promote cisplatin resistance in esophageal cancer. International Journal of Oncology 57:1382.
   PubMed Web of Science ®Google Scholar